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The L5178Y tumor-dormant state is established in DBA/2 mice by subcuta-
neous immunization and intraperitoneal challenge with a nonmetastatic line of
the methylcholanthrene-induced, syngeneic, T cell lymphoma, L5178Y (1, 2).
During the tumor-dormant state, clinically normal mice retain small numbers of
L5178Y cells in their peritoneal cavity for a prolonged period of time, ranging
from 2 to 12 mo. The progressive proliferation of L5178Y cells is restricted by
immunologic mechanisms involving cytolytic T lymphocytes and macrophages,
acting both individually (3, 4) and in synergy (5). Transfer of peritoneal cells
from a tumor-dormant mouse to the peritoneal cavity of a normal mouse results
in the rapid formation of an ascitic tumor. L5178Y cells that persist in a tumor-
dormant state eventually proliferate to form an ascitic tumor (1). The develop-
ment of ascitic tumors is preceded by the appearance in the peritoneal cavity of
macrophages that have increased immunosuppressive activity (6). These macro-
phages produce an immunosuppressive factor in vitro, recently identified as PE2
(our unpublished data), production of which can be inhibited by treatment of
macrophage cultures with indomethacin (7). The L5178Y cells that grow out at
the end of the tumor-dormant state are less susceptible to immune lysis than the
L5178Y cells that are used to initiate the tumor-dormant state (8). This pheno-
typic shift in the tumor cell population during progression of the tumor-dormant
state is caused by a immunoselection process (9, 10).
The production of PGE2 by macrophages before formation of ascitic tumors
suggested that this PGEj , suppresses the mechanisms by which progressive tumor
cell proliferation is restrained during the tumor-dormant state. To test this
hypothesis, we performed a series of in vivo and in vitro experiments with PGE2
and its synthetase inhibitor, indomethacin . This report presents experiments
which demonstrate that treatment of tumor-dormant mice with PGE2 terminates
the tumor-dormant state, with formation of ascitic tumors. Also, treatment of
cultures of peritoneal cells from tumor-dormant mice with PGE2 results in
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enhancement of tumor cell growth. Conversely, treatment of tumor-dormant
mice with indomethacin results in elimination of all recoverable tumor cells, and
treatment of cultures of peritoneal cells from tumor-dormant mice with indo-
methacin results in inhibition of tumor cell growth.
Materials and Methods
Animals.
￿
8-12-wk-old female DBA/2 mice were obtained from The Jackson Labora-
tories, Bar Harbor, ME. All mice were fed Purina mouse chow and given acidified tap
water ad libitum. They were housed in a temperature-controlled room with a cycle of 12
h of light and 12 h of dark.
Tumor Cells.
￿
The L5178Y cell line is a nonmetastatic T cell lymphoma induced in
DBA/2 mice with methylcholanthrene (1).
CultureMedium.
￿
Eagle's MEM was supplemented with 10% FCS, sodium pyruvate (1
mM), nonessential amino acids (0.1 MM), L-glutamine (2 mM), 15 mM Hepes, sodium
bicarbonate (1 .125 g/liter) and 50 Ag/ml gentamycin sulfate (Schering Corp., Kenilworth,
NJ).
Establishment of the L5178Y Tumor-dormant State.
￿
This procedure has been described
(1). Briefly, 105 in vivo-passaged L5178Y cells were implanted s.c. on the mid-ventral
surface of DBA/2 mice. 7-10 d later, the resultant 0.5-1 .0 cm diam nodule was surgically
excised, and 7 d later, mice were challenged i.p. with 5 X 104 L5178Y cells.
Partial Peritoneal Lavage (PPL).'
￿
Mice received an i.p. injection of 2.5 ml of sterile
pyrogen-free PBS, and the abdomen was massaged thoroughly to mix the PBS with the
peritoneal contents. The mice were then lightly anesthetized with ether and restrained
on a board, ventral side upward. A small area of the ventral surface was shaved, and 0.4-
2 ml of the PBS was removed from the peritoneal cavity with a 5 ml syringe fitted with a
25-gauge needle. The volume removed from each sampling was recorded. The recovered
peritoneal cells (PC) were pelleted and resuspended in the same volume of MEM.
Serial End-point Dilution Assay (SEPD)for Counting Tumor Cells (9).
￿
Single-cell suspen-
sions of peritoneal cell populations containing tumor cells were prepared from tumor-
dormant mice. 100 j,l of MEM was added to each well of a 96-well flat-bottomed microtiter
plate (Costar, Cambridge, MA). 100 jul of each cell suspension was then added to the first
well of each row, and a series of twofold dilutions was made through 24 wells. Each PC
suspension was titrated in quadruplicate. The plates were incubated at 37°C in a hu-
midified 5% C02 atmosphere and examined microscopically after 3 and 14 d incubation
for tumor cell growth. Wells containing the highest dilution of each cell suspension that
yielded positive tumor cell growth were identified, and the number of tumor cells in each
initial cell suspension was calculated.
Classification of Tumor-dormant Mice.
￿
Immunized and challenged mice were classified
as tumor-dormant if the number of tumor cells in the peritoneal cavity on the 25th d
after L5178Y cell challenge days post challenge; as determined by PPL and the SEPD
assay, was 1-2 X 105. Tumor-dormant mice were classified as "tumor-emerging" when
the number of tumor cells was >2 X 105 and <10'. Tumor-dormant mice were classified
as "tumor-emergent" when the number of tumor cells in the peritoneal cavity was >10'.
Tumor-dormant mice whose peritoneal cells yielded tumor cell growth when placed in
culture at 4 X 105 cells/well in a 96-well microtiter plate are referred to as "in vitro tumor-
progressor" tumor-dormant mice. Mice whose peritoneal cells yielded significantly fewer
tumor cells after 7 d culture as compared with the inception of culture are referred to as
"in vitro tumor-regressor" tumor-dormant mice.
Complete Peritoneal Lavage (CPL).
￿
Mice were killed by cervical dislocation, and the PC
were removed in two successive 5-ml peritoneal washouts with PBS. The PC were pelleted
by centrifugation, resuspended in 4 ml MEM, and counted by hemocytometer. This
technique recovered >99% of the PC (9).
' Abbreviations used in this paper:
￿
CPL, complete peritoneal lavage; PC, peritoneal cells; PPL,
partial peritoneal lavage; SEPD, serial end-point dilution assay.LIU ET AL.
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In Vitro Tumor-dormant Peritoneal Cell System.
￿
Tumor-dormant mice were killed and
CPLs were performed. The recovered PC were brought to a concentration of 4 X 106
cells/ml . A volume of 0.5 ml of the PC suspension from each mouse was used for
quantitation of tumor cells using the SEPD assay, and the numbers of tumor cells ?er 4
X 105 PC was calculated. 1/1o ml of the remaining PC suspension (containing 4 X 10 PC)
from each mouse was added to individual wells of a 96-well microtiter flat-bottomed
culture plate (Costar). The wells were then divided into sets as indicated in the text, and
the wells of each set received 0.1 ml of MEM, PGE2, or indomethacin, depending on the
experimental design. The plates were incubated for 7 d at 37°C. The cells in the wells
were then suspended and the tumor cells were quantitated by the SEPD assay and
compared with the number of tumor cells calculated to be in the wells at the start of the
cultures.
In Vitro PC Culture Supernatant PGE2 RIA. Peritoneal cells were removed from
individual tumor-dormant mice and the number of tumor cells per 4 X 105 PC for each
mouse was determined by SEPD assay. Cultures were then prepared as described in the
previous section. After 7 d incubation at 37'C, the cell-free supernatants were removed
and tested for PGE2 by RIA (' 25I-PGE2 RIA kit purchased from New England Nuclear,
Boston, MA). This assay could measure as little as 0 .13 pg/ml PGE2. The cells from the
wells supplying the supernatants were then suspended, and the number of tumor cells in
each suspension was quantitated by the SEPD assay. The number of tumor cells in each
well at the beginning and end of culture was then compared, and each well was classified
as yielding tumor cell growth or no growth.
Separation of Nonadherent PC.
￿
Nonadherent PC were separated from whole PC by
adherence to plastic petri dishes.
PGE2 or Indomethacin Preparation.
￿
PGE2 (Upjohn Co., Kalamazoo, MI) and Indometh-
acin (Sigma Chemical Co., St. Louis, MO) were dissolved in 100% ethanol in a concentra-
tion of 10 m /ml as stock solution and kept in a -20°C freezer until used. The working
solution, 10- M, was prepared by dilution in PBS or MEM.
In Vivo Protocol to Determine Effects of PGE2 or Indomethacin on Tumor-dormant
State. The protocol illustrated in Fig. 1 was used. A PPL was performed on all L5178Y
cell-immunized and challenged mice 25 d after L5178Y cell challenge. The number of
tumor cells in each lavage was determined by the SEPD assay, and mice were classified as
tumor-dormant on the basis of the number of tumor cells in their peritoneal cavity (see
section on classification of tumor-dormant mice) . The tumor-dormant mice were then
divided into groups, with each group having equal numbers of mice with comparable
tumor burdens. The groups were then treated with PGE2 i.p. for 10 d, or with Indometh-
acin as indicated in the text. 4 d after the end of PGE2 treatment, or as indicated in the
indomethacin experiments, the mice were killed and CPLs were performed. 10% of the
PC from each mouse was used to quantitate the number of tumor cells in the lavage, and
the remaining PC were placed in culture flasks at a low cell/surface area ratio to minimize
cell-cell contact and to permit a single tumor cell to grow if present. The tumor cell
numbers in each mouse before and after treatment were then compared.
Results
Effect of PGE2 on L5178Y Tumor-dormant State.
￿
To determine whether the
PGE2 produced by peritoneal macrophages in tumor-dormant mice before for-
mation of ascitic tumors is responsible for termination of the tumor-dormant
state, we administered 100 Wg of PGE2 i .p. to mice daily for 10 d using the
protocol shown in Fig. 1 . In this protocol, the number of tumor cells in each
mouse was quantitated before treatment by PPL and SEPD assay, and after
treatment by CPL and SEPD assay.
In the experiment shown in Table 1, 12 tumor-dormant mice received PGE2
and 12 tumor burden-matched tumor-dormant mice received 5% ethanol as
controls. 4 d after the last inoculation of PGE2, 9 of 12 (75%) mice had tumor1262
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FIGURE 1.
￿
Protocol for establishment and treatment of the L5178Y tumor-dormant state.
L5178Y cell-immunized and -challenged mice were subjected to a partial peritoneal lavage
on the 25th d after challenge. Tumor burdens were quantitated by the SEPD assay, and mice
were classified as tumor-dormant if tumorcellswere present at <2 X 105cellsin theperitoneal
cavity. 5 d after partial peritoneal lavage, PGE2 or indomethacin was administered for the
number of days indicatedin the text, and CPLs were performed either 4 dafterthe final day
of PGE2 treatment, or as indicated in the text for the indomethacin experiments. The final
tumor burdens in the CPLs were quantitated, and the tumor burdens before and after
treatmentwere compared in individual mice.
TABLE I
Effect ofPGE2 on the L5178Y Tumor-dormantState
Emergent mice:
￿
3/12(25%)
￿
9/12(75%)
PGE2 was administered i.p. to tumor-dormant mice twice daily for 10 d, 50 wg per
inoculation. Control tumor-dormant mice received inoculations of 0.1 ml of 5%
ethanol. Tumor-dormant mice were selected for the experiment if each containedat
least 1 and <200,000 tumor cells in its peritoneal cavity 25 d after L5178Y cell
challenge, as determined by PPLs and SEPD assays. 24 tumor-dormant mice were
divided into two groups on the basis of their tumorburdens. Treatmentwas begun 5
d after PPL. 4 d after the final inoculation of PGE2, CPLs were performed and the
final tumor burdens were determined by SEPD assays.
* Cure: no tumorcellsin the peritoneal cavity at theendof theexperiment. TD (tumor
dormant): at least I and <2 X 105 tumor cells. Emerging: >2 X 105and <10' tumor
cells. Emergent: >10' tumor cells. There was a significant difference between the
number ofemergent mice in the two groups (Mann-Whittney U test, p <0.002).
$ Thesemice died with ascitic tumors before the endof the experimental period.
burdens of >107 cells, and were classified as tumor-emergent, and one mouse
was emerging from the tumor-dormant state. In contrast, only 3 of 12 (25%) of
the ethanol-treated mice were tumor-emergent, a level that normally occurs
Ethanol-treated
Number of L5178Y
cells (X10')
Before After
mice
Tumor state*
Number
cells
Before
PGE2-treated
of L5178Y
(X10')
After
mice
Tumorstate
1.6 0 Cure 0.8 >10,000.0 Emergent
2.4 51 .2 TD 2.0 409.0 Emerging
3.2 1.2 TD 4.8 102.4 TD
7.2 6.4 TD 4.8 >10,000.0 Emergent
8.0 25 .6 TD 6.4 >10,000.0 Emergent
9.6 102.4 TD 7.2 >10,000.0 Emergent
12.8 0.1 TD 8.0 >10,000.0 Emergent
12.8 38.4 TD 9.6 >10,000.0 Emergent
16.0 >10,000.0 Emergent 16.0 6.4 TD
19.2 153.6 TD 28.8 >10,000.0 Emergent
19.2 >10,000.0 Emergent 12.8 >10,000.0 Emergent*
25.6 >10,000.0 Emergent 19.2 >10,000.0 Emergent$C7
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￿
Tumor cell growth in PC cultures prepared from different tumor-dormant mice.
Peritoneal cells were removed from 26 tumor-dormant mice by CPL. For each mouse, the
number of tumor cells per 4 X 105 PC was determined by the SEPD assay, and 4 X 105 PC
were planted in each ofthreewells ofa96-well microtiter plate. After7 dincubation at 37°C,
thenumber oftumor cells was determined in each of thethreewells of each set, andthe mean
number of tumor cells and SEM per set was calculated. The mean number of tumor cells in
cultures prepared from each mouse at the beginningand at the end of incubation is shown.
during such a 3-wk experimental period. In additional experiments, we found
that tumor burdens increase in PGE2-treated tumor-dormant mice after only 5
d of treatment, as compared with ethanol-treated controls.
Tumor Cell Growth in Cultures ofPeritoneal Cellsfrom Tumor-dormant Mice.
￿
To
study the mechanisms by which PGE2 produced its tumor cell growth-enhancing
effect in tumor-dormant mice, we used an in vitrosystem. In this assay, described
previously (1), 4 X 105 PC from a tumor-dormant mouse are placed in individual
wells of a 96-well microtiter plate. We reported previously (1) that the small
number oftumor cells present in these PC do not grow out during incubation at
37°C.
Fig. 2 shows the growth of tumor cells in PC cultures prepared from a large
number of tumor-dormant mice. PC from 26 tumor-dormant mice were har-
vested, the number oftumor cells per 4 X 105 PC in each mouse was quantitated
by the SEPD assay, and the remaining PC were placed in wells of a 96-well
microtiter plate, 4 X 105 cells/well, threewells/mouse. The plates were incubated
for 7 d at 37°C, and the number of tumor cells in each well was quantitated by
the SEPD assay. The mean number of tumor cells in the PC at inception and
termination of culture for each mouse are shown in Fig. 2. During the 7-d
incubation period, tumor cells proliferated in the PC cultures prepared from
some tumor-dormant mice, and the mice providing these PC are referred to as
"in vitro tumor-progressor" mice. Tumor cells failed to grow out in the PC
cultures prepared from other tumor-dormant mice, and the miceprovidingthese
PC are referred to as "in vitro tumor-regressor" mice.
Effect of PGE2 on Tumor Cell Growth in PC Cultures Prepared from In Vitro
Tumor-progressor and In Vitro Tumor-regressor Tumor-dormant Mice.
￿
To deter-1264
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FIGURE 3. The effect of PGE2 on tumor cell growth in PC cultures prepared from a
representative in vitro tumor-progressor tumor-dormant mouse (1, 10) and in vitro tumor-
regressortumor-dormant mouse (2, O). Peritoneal cells were collected, tumor burdens were
determined, and PC cultures were prepared as described in Fig. 2. 12 wells were prepared
from each mouse, with 6 of the wellsreceiving ethanol-containing medium (p, 0) and 6 wells
receiving PGE2 (/, 9) at 10'6 M. After 2, 4, and 7 d incubation, the tumor cells in two wells
of each set were counted by the SEPD assay. The isolated symbols represent the number of
tumorcells in the peritoneal cavity of each mouse. Results are mean numbers of tumor cells
per set.
minewhether PGE2 would stimulate the growth oftumor cells in PC populations
from in vitro tumor-regressor tumor-dormant mice, we added PGE2, at 10-6 M,
to 6 of 12 PC wells prepared from a number of tumor-dormant mice; the other
6 wells from each mouse received ethanol-containing MEM. After 2, 4, and 7 d
incubation, the cells in two ofthe PGE2-treated wells and in two ofthe untreated
wells from each mouse were suspended, and the tumor cells in the suspensions
were quantitated. Fig. 3 shows the effects of PGE2 on tumor cell growth in PC
cultures prepared from an in vitro tumor-progressor mouse (mouse 1), and an
in vitro tumor-regressor mouse (mouse 2). In mouse 1, tumor cells increased in
number in the ethanol-treated control wells, and PGE2 had no effect on this
tumor cell growth. In mouse 2, tumor cells decreased in number during the 7-d
incubation period in the control wells, and the addition ofPGE2 resulted in rapid
tumor cell growth at a rate equal to the rate of growth of tumor cells in the
cultures prepared from mouse 1. Similar results have been found in many
matched pairs of in vitro tumor-progressor and in vitro tumor-regressor tumor-
dormant mice. In other experiments with pure tumor cell cultures, we found
that PGE2 at 10-6 M had no direct effect on the rate oftumor cell growth during
72 hincubation at 37 DC (datanotshown). Thesedata suggestthatPGE2 enhances
tumor cell growth in PC cultures from in vitro tumor-regressor tumor-dormant
mice by subverting the function of those host cells that normally restrain tumor
cell growth .
Production ofPGE2 in PC Culturesfrom In Vitro Tumor-progressor Tumor-dormant
Mice. The parallel growth curves of tumor cells in the PGE2-treated and
untreated wells of PC prepared from mouse 1 in the above experiment suggested
that PGE2 was being produced in the untreated wells. To test this possibility, we
prepared PC cultures from 17 tumor-dormant mice, one well/mouse, and after
7 d culture, we collected the cell-free supernatants from each well and measuredTABLE II
Correlation Between Tumor Cell Growth In Vitroand PGE2
Production in PC Culturesfrom Tumor-dormant Mice
Total
number of
wells*
LIU ET AL
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Wells with tumorcell
￿
Wells with tumorcell
increase*
￿
decrease
Wellswith PGE2 ￿Wells with PGE2 Number
￿
(>3 ng/ml)i
￿
Number
￿
(>3 ng/ml)
17 11 8(73%) 6 0(0%)
* Each well contained4 X 105 PC from adifferenttumor-dormant mouse.
Achange in tumorcell numbers equal to or greater than fourfoldduring
the 7-d incubation period.
$PGE2 levels in the culture wells in which tumor cells did not increase
were <2.2 ng/ml. 8 of the 11 wells in which tumor cells increased
contained >4.3 ng/ml. Statistical analysis by Student's t test indicates
that the difference in PGE2 levels between the two groups is significant
(p < 0.001).
the PGE2in the supernatants by RIA. The PC in thesewells were then suspended,
and the number oftumor cells in each suspension was determined by the SEPD
assay. As seen in Table II, there was an excellent correlation between the ability
of tumor cells to proliferate and the amount of PGE2 in each well. However,
there was no correlation between the total number of tumor cells in specific
wells and the amount of PGE2 (data not shown).
To identify the cell population that produces PGE2 in the PC cultures from in
vitro tumor-progressor mice, and to exclude the possibility that these cultures
contained PGE2-producing L5178Y cells, we transferred the PC from in vitro
tumor-progressor cultures to tissue culture flasks. The L5178Y cells proliferated
in the flasks and were passaged until no host cells remained. The supernatants
ofthese tumor cell cultures were then tested for PGE2 and none was found. We
can conclude from this experiment that PGE2 is produced by host cells rather
than by tumor cells.
Effect of Indomethacin on the Tumor-dormant State.
￿
The ability of PGE2 to
cause formation of ascitic tumors in tumor-dormant mice and promote tumor
cell growth in vitro suggested that administration of an inhibitor of PGE2
synthetase, indomethacin, mighteliminate tumor cells from tumor-dormant mice
and inhibit tumor cell growth in vitro. To test this possibility, indomethacin was
administered into the peritoneal cavity oftumor-dormant mice from Alzet mini-
osmotic pumps. These pumps, implanted subcutaneously on the ventral surface
with a size PE 60 catheter leading into the peritoneal cavity, delivered a contin-
uous amount of indomethacin, 50 Ag/d, or ethanol for 14 d; new pumps were
not reimplanted in the 21-d-incubation mice. At selected days after implantation
of the pumps, mice were killed and all PC were placed in culture, 10% of the
PC in a SEPD assay, and the remaining PC in culture flasks at a low cell/culture
surface area ratio to minimize cell-cell contact during the incubation period. As
seen in Table III, at 7, 14, and 21 d after implantation ofthe mini-pumps, there
were no recoverable tumor cells in the indomethacin-treated mice as compared
with the ethanol-treated controls.
Effect ofIndomethacin on Tumor Cell Growth in PC Culturesfrom Tumor-dormant1266
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Treatment
TABLE III
Effect of Indomethacin on the L5178Y Tumor-dormant State
Mice with no recoverable tumor cells vs . total mice* on :
Day 7
￿
Day 14
￿
Day 21
Ethanol
￿
0/3(0%)
￿
0/14(0%)
￿
2/9 (22%)
Indomethacin 3/3(100%) 9/14(64%) 8/11(73%)
Mice received either 50% ethanol vol/vol or indomethacin (50 Jag/d i.p .) for the
designated number of days, delivered at 0.6 ul/h by catheter from Alzet mini-osmotic
pumps, which were implanted subcutaneously on the ventral surface .
* The number of mice that had no recoverable tumor cells on cultivation of all PC at
the end of the designated number of days of treatment divided by the total number
of mice in each group .
FIGURE 4 .
￿
The effect of indomethacin on thegrowth of tumor cells inPC cultures prepared
from an in vitro tumor-progressor tumor-dormant mouse . PC were collected and placed in
wells of a 96-well microtiter dish, 4 X 10 5 cells/well . Indomethacin at the indicated molarity
was added to wells, three wells per molarity, and the tumor cells were counted after 7 d
incubation by the SEPD assay . The results are expressed as the mean numbers of tumor cells
(±SEM) for each set .
Mice.
￿
The production ofPGE2 in cultures ofPC from in vitro tumor-progressor
tumor-dormant mice suggested that indomethacin added to such cultures at
their inception might inhibit tumor cell growth . We therefore added indometh-
acin at 10-5 , 10-6 , and 10' -' M to wells of PC from in vitro tumor-progressor
tumor-dormant mice, three wells per molarity, and 7 d later, we quantitated the
tumor cells in the medium-andindomethacin-treated wells. These concentrations
ofindomethacin completely inhibitPGE2 production in PC cultures from in vitro
tumor-progressor tumor-dormant mice (data not shown) . As seen in Fig . 4,
treatment of PC tumor-progressor cultures with indomethacin at 10' and 10-6
M inhibited tumor cell growth . In experiments with pure tumor cell cultures,
we found that indomethacin at 10-5 M had no direct effect on L5178Y cell
growth (data not shown) . These data suggest that indomethacin inhibits tumor
cell growth by preventing PGE2-mediated suppression of those host cells that
normally restrain tumor cell growth .
Dose Effect of PGE2 in Presence of Indomethacin on Tumor Cell Growth in PC
Cultures Prepared from In Vitro Tumor-regressor Tumor-dormant Mice. We next
evaluated the dose effect of PGE2 on the growth of tumor cells in PC cultures
from in vitro tumor-regressor tumor-dormant mice . Indomethacin wasadded toLIU ET AL .
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FIGURE 5 .
￿
The effect of indomethacin, 10-5 M, on the tumor cell growth enhancing activity
of PGE2, 10-6 M, in PC cultures prepared from tumor-dormant mice . A pool of PC from two
in vitro tumor-regressor tumor-dormant mice wasprepared, and indomethacin and PGE2 were
added to wells, three wells per set . Tumor cells were counted after 7 d incubation . The results
are expressed as the mean numbers of tumor cells (±SEM) for each set .
each well in this experiment in order to inhibit endogenous PGE2 production .
We first determined whether indomethacin would interfere with the tumor cell
growth-enhancing effects of PGE2 . As seen in Fig . 5, PGE2 enhanced tumor cell
growth . Indomethacin at 10-6 M inhibited tumor cell growth, but had no
inhibitory effect on the tumor cell growth-enhancing effect of 10-6 M PGE2 .
Fig . 6 shows the effect of various doses of PGE2 in the presence of 10-6 M
indomethacin on tumor cell growth . The addition of 10-5-10-7 M PGE2 stimu-
lated tumor cell growth, and lower doses ofPGE2 had no effect .
Identification of Host Cells that Restrain Tumor Cell Growth in PC Cultures from
In Vitro Tumor-regressor Tumor-dormant Mice . To identify the PC population
that was responsible for the restraint on L5178Y cell growth in wells prepared
from in vitro tumor-regressor mice, we separated the nonadherent peritoneal
cells by a plastic-adherence step, and cultured both the complete and the
nonadherent PC at high cell density. Since L5178Y cells are nonadherent, they
remained in the nonadherent cell population .PGE2 was added to one-half of the
number of wells of each PC population, and tumor cells were quantitated 7 d
later by the SEPD assay .
As seen in Fig. 7, tumor cell growth did not occur in the untreated complete
PC cultures, but didoccur when PGE2 wasaddedto the cultures . In theuntreated
nonadherent PC cultures, tumor cells grew and PGE2 had no effect on tumor
cell growth . These findings indicate that adherent cells are involved in the
restraint on tumor cell growth . Yet to be determined is the role of the nonad-
herent PC in tumor cell growth restraint, and whether the adherent cells lyse or
arrest the proliferation of tumor cells, or are required as accessory cells for
nonadherent cells to restrain tumor cell proliferation .
Discussion
Prostaglandins of the E series are important regulators of many components
of the immune response (11) . Among its other effects on the immune system,
PGE2has been reported to (a) inhibit theproduction of IL-2 (12, 13), (b) stimulate1268
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FIGURE 6.
￿
The effect of graded doses ofPGE2 in the presence of 10-5M indomethacin on
the growth of tumor cells in PC cultures prepared from a pool of four in vitro tumor-regressor
tumor-dormant mice . The procedure used in Fig . 5 was followed. Results are mean numbers
of tumor cells (±SEM) per set .
the production of suppressor T lymphocytes (14-16), and (c) inhibit the clonal
proliferation of B lymphocytes (17) . Macrophages produce large amounts of
PGE2 on appropriate stimulation (18, 19) . This PGE2 can downregulate macro-
phage tumoricidal activity and may be an important self-regulating feedback
mechanism for macrophage activation (20-22). Macrophages from tumor-bear-
ing mice produce increased amounts of PGE2 (23), and patients with various
types of cancer have either increased levels of PGE2 and PGE2 metabolites (24-
27), or have impaired immune responses that can be stimulated in vitro with
indomethacin (28) . Administration of inhibitors of PG synthesis in mice has been
found to retard or suppress tumor growth (29, 30), and to improve cell-mediated
immune functions when added to their spleen cells in vitro (29, 31) . However,
in some tumors, such as B-16 melanoma, the major cyclooxygenase metabolite
is PGD2 rather than PGE2, and inhibitors of PG synthesis produce tumor
enhancement rather than tumor inhibition (32) .
To date, the effects of PGE2 and indomethacin on tumor growth have been
evaluated in animal models in which tumor cells have either been induced or are0
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￿
Tumorcell growth in cultures of the complete and the nonadherent populations
of PC from an in vitro tumor-regressor tumor-dormant mouse. Theeffect of PGE2at 10-6 M
on each set of cultures is shown. The PC were harvested by CPL. One-half of the PC were
incubated for 1 h on plastic tissue culture plates and the nonadherent cells (containing the
nonadherent tumor cells) removed. Culture wells were prepared with either 4 X 105 PC or
the nonadherent equivalent per well, four wells per group. Two wells from each set was
then treated with PGE2, andthecultures were incubatedat 37°C for 7 days. The tumorcells
in each well were then counted by the SEPD assay. Results are mean numbers of tumorcells
(±SEM) per set.
growing after transplantation. Animal models of tumor dormancy are clinically
relevant, in that small numbers oflethal tumorcells persist forprolongedperiods
of time without producing disease (33, 34). Such models may be analogous to
those patients who are in clinical remission after treatment ofa primary tumor
and who will develop a recurrent tumor. Likely examples of tumor-dormant
states in human cancer are adenocarcinomas ofthe breast, which can grow out
in the surgical scar tissue ofa mastectomy as long as 50 yr after surgical removal
of a histologically identical adenocarcinoma (35), and malignant melanomas,
which can grow out in the liver many years after removal of a uveal malignant
melanoma (36, 37).
In this report we described the effects of PGE2 on tumor cell growth under
conditions in which tumor cells were maintained in a tumor-dormant state.
Previous evidence forthe regulatory roleofPGE2in the L5178Y tumor-dormant
system consists of our finding (6) that macrophages with increased immunosup-
pressive activity appear in the peritoneal cavity of tumor-dormant mice just
before the appearance ofascitic tumors. These macrophages produce an immu-
nosuppressive factor in vitro, now identified as PGE2 (our unpublished data),
production of which is inhibited by indomethacin (7). Our demonstration that
exogenous PGE2 stimulates formation of ascitic tumors in tumor-dormant mice
provides further support for the hypothesis that PGE2, which is produced by
peritoneal macrophages, terminates the tumor-dormant state.1270
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We found that the PC cultures from in vitro tumor-progressor tumor-dormant
mice (in which tumor cells proliferate progressively) produce more PGE2 than
PC cultures from in vitro tumor-regressor tumor-dormant mice (in which tumor
cells do not proliferate), and that the addition of PGE2 to tumor-regressor
cultures converts them into tumor-progressor cultures. The variations in the
ability of tumor cells to proliferate in PC cultures from tumor-dormant mice
may reflect the variations in the duration of the tumor-dormant state among
mice. It is possible, however, that the differences between tumor-regressor and
tumor-progressor cultures may reflect ongoing cycles within an individual mouse,
of macrophage activation and deactivation mediated by IFN--Y released from
stimulated T cells, and by PGE2 released from activated macrophages. If this is
so, then an individual mouse may go through cycles of tumor-progression and
tumor-regression, the net result of which would be to maintain cytolytic or
cytostatic control on tumor cell proliferation without killing all tumor cells. The
demonstrations that indomethacin can both eliminate recoverable tumor cells
from tumor-dormant mice and inhibit the proliferation of tumor cells in PC
cultures from in vitro tumor-progressor tumor-dormant mice support the hy-
pothesis that macrophage activation and deactivation is a feature of the tumor-
dormant state, and that the inhibition of a suppressor of macrophage activation
permits macrophages to kill all tumor cells.
The complete analysis of the L5178Y tumor-dormant model is limited by
certain characteristics of the model. Since large numbers of peritoneal cells are
required for the preparation of multiple PC cultures, it is necessary to kill the
tumor-dormant mouse to obtain these cells. It is therefore not possible, in an
individual mouse, to measure the changes in antitumor activity ofperitoneal cell
populations as that mouse proceeds through the tumor-dormant state towards
termination. It is also not possible to compare one tumor-dormant mouse with
another because of the large variations in the activity of the immune response
and in the duration of the tumor-dormant state among mice that have been
immunized and challenged with L5178Y cells at the same time.
The in vitro assay described here does provide a system in which the PC
population of a single tumor-dormant mouse can be studied under controlled
conditions. An important feature of this in vitro system is that it is quantitated
in the same way as the in vivo model, e.g., by tumor cell proliferation . The
tumor cell growth-enhancing effects of exogenous PGE2, when administered
both in vivo and in vitro, and the tumor cell growth-inhibiting effects of
indomethacin, when administered both in vivo and in vitro, support the validity
of the in vitro system as a correlate of the in vivo model. This in vitro system,
therefore provides an opportunity to evaluate the mechanisms that maintain and
terminate the tumor-dormant state in vivo. Experiments to identify the mecha-
nisms by which PGE2 and indomethacin produce their tumor cell growth-
enhancing and -inhibiting effects in tumor-dormant mice are in progress, and
will constitute a subsequent paper in this series.
Our analysis of the L5178Y tumor-dormant model to date suggests that
L5178Y cells are maintained in a tumor-dormant state by peritoneal macro-
phages and T lymphocytes. These cells are upregulated to a cytotoxic state by
lymphokinesreleasedfrom L5178Y-stimulated helper Tlymphocytes, and down-LIU ET AL.
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regulated to a noncytotoxic state by PGE2 released from activated macrophages.
The PGE2 may downregulate macrophage cytolytic activity by acting directly on
macrophages and downregulate T lymphocyte cytolytic activity either directly
or indirectly by stimulating suppressor T lymphocytes. Both macrophages and
cytolytic T lymphocytes may be downregulated before all tumor cells are killed,
thereby permitting some tumor cells to escape lysis and persist in a tumor-
dormant state. The tumor-dormant state may end when phenotypic variants of
the L5178Y cells, which are less susceptible to immune lysis and less immunogenic
than the L5178Y population used to initiate the tumor-dormant state, are
selected by the immune response and become dominant in the peritoneal cavity
of tumor-dormant mice (9, 10). These poorly immunogenic tumor cell variants
may not stimulate helper T lymphocytes to produce the regulatory lymphokines
that are needed to maintain an effective anti-tumor cell response and maintain
the tumor-dormant state. The L5178Y tumor-dormant model can be used to
study immunoregulatory circuits that affect tumor growth,and to test therapeutic
agents that can be given to patients who are in clinical remission after treatment
of a primary tumor and who have a high statistical probability of developing a
recurrent tumor.
Summary
Immunization and intraperitoneal challenge of DBA/2 mice with E5178Y
lymphoma cells results in the suppression and maintenance of the L5178Y cells
in a tumor-dormantstate in theperitoneal cavity formany months. Cell-mediated
immune responses involving lymphocytes and macrophages are involved in
maintenance of the tumor-dormant state. Macrophages that have increased
immunosuppressive activity and that produce increased amounts of PGE2 appear
in the peritoneal cavity of tumor-dormant mice before the breakdown of the
tumor-dormant state and formation of ascitic tumors.
We report here that the tumor-dormant statecan be terminated with formation
of ascitic tumors by treatment of tumor-dormant mice with PGE2. Treatment
with indomethacin results in inhibition of tumor cell growth and elimination of
all recoverable tumor cells. Cultures of peritoneal cells (PC) from mice harboring
L5178Y cells in a tumor-dormant state were used to analyze the PGE2 and
indomethacin effects. Tumor cells did not grow out in the high-cell density PC
cultures prepared from many tumor-dormant mice, but addition of PGE2 to
these cultures resulted in tumor cell growth. The tumor cell growth that did
occur in the PC cultures from some tumor-dormant mice was associated with
PGE2 production by the associated host cells, and the addition of indomethacin
to these cultures inhibited both PGE2 synthesis and tumor cell growth. Removal
of plastic-adherent cells from the PC cultures eliminated the restraint on tumor
cell growth. These experiments suggest that L5178Y tumor cells are maintained
in a tumor-dormant state by host peritoneal cells, which are under PGE2 regu-
lation.
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